Cargando…
Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC)
The coronavirus disease 2019 (COVID-19) pandemic has affected the number of completed clinical trials, particularly in oncology. Between 80–85% of all lung cancers are non-small cell lung cancer (NSCLC), and of these, between 2–3% have an EGFR exon 20 insertion, which is associated with increased ce...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Scientific Literature, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482802/ https://www.ncbi.nlm.nih.gov/pubmed/34565792 http://dx.doi.org/10.12659/MSM.934854 |